The Otsuka Pharmaceutical Co Ltd's Abilify MyCite tablets are the first drug with a digital ingestion tracking system to be approved in the U.S., according to a statement from the FDA. 

The tablets, which have a sensor embedded in the pill, are meant to allow easier treatment of schizophrenia, bipolar disorder and some depression, according to the statement. The pill's sensor sends a message to a wearable patch, which then relays information on digestion to a mobile application that allows patients to track their medication on their smart phones. 

With permission, caregivers and physicians can also track the patient's medication through a web-based portal. 

"Being able to track ingestion of medications prescribed for mental illness may be useful for some patients," Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in a statement.